Carbohydrate metabolism disorders and cerebral atherosclerosis in patients with ischemic cerebrovascular diseases

Cover Page

Abstract

Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS) facilitate the development of ischemic cerebrovascular diseases. This article presents the results of examination of patients with ischemic cerebrovascular diseases associated with T2DM and MS. We have found that T2DM adversely affects the progression of atherosclerosis in patients with cerebrovascular diseases, and activity of the atherosclerotic process in the great cerebral arteries directly depends on the duration of carbohydrate disorders.

About the authors

K. V. Antonova

Research Center of Neurology, Moscow

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

R. B. Medvedev

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

A. A. Shabalina

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

O. V. Lagoda

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

M. M. Tanashyan

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой,7-й вып. М., 2015.
  2. Гулевская Т.С., Моргунов В.А. Патологическая анатомия нарушений мозгового кровообращения при атеросклерозе и артериальной гипертонии. М.: Изд-во «Медицина», 2009.
  3. Дедов И.И., Шестакова М.В. Феномен «метаболической памяти» в прогнозировании риска развития сосудистых осложнений при сахарном диабете. Терапевтич. архив. 2015;10: 4–10.
  4. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007-2012 гг.» Под ред. И.И. Дедова, М.В. Шестаковой. Сахарный диабет 2013 (спецвыпуск № 2).
  5. Суслина З.А., Иллариошкин С.Н., Пирадов М.А. Неврология и нейронауки – прогноз развития. Анн. клинич. и эксперим. неврологии. 2007; 1: 5–9.
  6. Суслина З.А., Варакин Ю.Я. Эпидемиологические аспекты изучения инсульта. Время подводить итоги. Анн. клинич. и эксперим.неврологии. 2007; 1: 22–28.
  7. Суслина З.А., Пирадов М.А., Домашенко М.А. Инсульт: оценка проблемы (15 лет спустя). Журн. неврол. и психиатр. 2014;11: 5–13.
  8. Танашян М.М. Лагода О.В., Антонова К.В. Сосудистые заболевания головного мозга и метаболический синдром (методические рекомендации). М., 2011.
  9. Танашян М.М., Кунцевич Г.И., Кудухова А.В. и др. Атеросклеротическое поражение сонных артерий у больных с ишемическими цереброваскулярными заболеваниями на фоне метаболического синдрома. Клинич. неврол.2012; 2: 3–8.
  10. Танашян М.М., Орлов С.В., Медведев Р.Б. и др. Метаболический синдром и нарушения мозгового кровообращения. Анн. клинич. и эксперим. неврологии. 2009; 3 (3): 41–47.
  11. Танашян M.M., Антонова К.В., Лагода О.В. и др. Острые нарушения мозгового кровообращения и сахарный диабет 2 типа. Анн.клинич. и эксперим. неврологии. 2014; 8 (3): 4–8.
  12. Adams J.N., Martelle S.E., Raffield L.M. et al. Analysis of Advanced Glycation End Products in the DHS Mind Study. J Diabetes Complications.2015; Nov 30. Eur Neurol. 2010; 63 (5): 267–278.
  13. Ashtari F., Salari M., Aminoroaya A. et al. Metabolic syndrome in ischemic stroke: A case control study. J Res Med Sci. 2012; 17 (2): 167–170.
  14. Borhani-Haghighi A., Emami M., Vasaksi A.S. et al. Large-vessel stenosis in the patients with ischemic stroke in Iran: Prevalence, pattern, and risk factors. Journal of Vascular and Interventional Neurology. 2015; 8 (1):11–16.
  15. Bosevski M., Stojanovska L. Progression of carotid-artery disease in type 2 diabetic patients: a cohort prospective study. Vascular Health and Risk Management. 2015; 11: 549–553.
  16. Bosevski M. Carotid artery disease in diabetic patients. Prilozi. 2014; 35 (3): 149–162.
  17. Chantler P.D., Shrader C.D., Tabone L.E. et al. Cerebral cortical microvascular rarefaction in metabolic syndrome is dependent on insulin resistance and loss of nitric oxide bioavailability. Microcirculation. 2015; 22 (6): 435–445.
  18. de Weerd M., Greving J.P., Hedblad B. et al. Prediction of asymptomatic carotid artery stenosis in the general population: identification of high-risk groups. Stroke. 2014; 45 (8): 2366–2371.
  19. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factor s through stable coronary artery disease). Circulation. 2006; 114 (25): 2850–2870.
  20. Holman R.R., Paul S.K., Bethel M.A. et al. Neil HA10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589.
  21. Howard B.V., Roman M.J., Devereux R.B. et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008 Apr 9; 299 (14): 1678–1689.
  22. Hu G., Sarti C., Jousilahti P. et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke. 2005 Dec; 36 (12): 2538–2543.
  23. IDF Diabetes Atlas, Seventh edition, 2015. Электронный ресурс http://www.diabetesatlas.org.
  24. Khaw K., Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol. 2006; 17 (6): 637–643.
  25. Li M., Li Y., Liu J. Metabolic syndrome with hyperglycemia and the risk of ischemic stroke. Yonsei Med J. 2013; 54 (2): 283–287.
  26. Maksimovic M., Vlajinac H., Radak D. et al. Relationship between peripheral arterial disease and metabolic syndrome. Angiology. 2009; 60:546.
  27. Mattishent K., Loke Y.K. Bi-directional Interaction Between Hypoglycaemia And Cognitive Impairment In Elderly Patients Treated with Glucose Lowering Agents: Systematic Review and Meta-analysis. Diabetes Obes Metab. 2015; 17 (1): 3–5.
  28. Messier C., Awad N., Gagnon M. The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia. Neurol. Res. 2004; 26 (5): 567–572.
  29. Paciaroni M., Bogousslavsky J. Primary and secondary prevention of ischemic stroke.
  30. Paneni F., Volpe M., Lüscher T.F, Cosentino F. SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory: Bringing All the Strands Together. Diabetes. 2013; 62 (6): 1800–1807.
  31. Tabatabaei-Malazy O., Fakhrzadeh H., Sharifi F. et al. Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients. Journal of Diabetes and Metabolic Disorders. 2015; 14: 84.
  32. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159–2167.
  33. Zhao W., Katzmarzyk P.T., Horswell R. et al. Sex Differences in the Risk of Stroke and HbA1c among Diabetic Patients. Diabetologia. 2014; 57 (5): 918–926.
  34. Zhou H., Zhang X., Lu J. Progress on diabetic cerebrovascular diseases. Bosnian Journal of Basic Medical Sciences. 2014; 14 (4): 185–190.

Statistics

Views

Abstract: 1366

PDF (Russian): 735

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2016 Antonova K.V., Medvedev R.B., Shabalina A.A., Lagoda O.V., Tanashyan M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies